With US Senate Wins In Georgia, Democrats Gain Path For Rx Price Reform, But It May Be Lower Priority
Razor-thin majorities in both chambers of Congress mean Democrats can’t enact a bold agenda, and the pandemic and attendant recession mean that the initial legislative focus won’t be on Rx issues.
You may also be interested in...
Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing ‘behind us’ with a legislative compromise.
Proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
Rx Industry Reassessing Political Donations In Wake Of Riots; Shift Towards Democrats Already Underway
Donation patterns in 2020 campaign suggest rethinking may have taken place before the mob attacked the Capitol, potentially an assessment of the election prospects or because of Trump’s policies during his term.